natgillin/translations-raw huggingface dataset:
AUC0- 48 time · ng/ ml
AUC0-48 hour · ng/ ml
10 Metabolisme og elimination:
Metabolism and elimination:
Buprenorphin metaboliseres ved 14- N- dealkylering og glukuronid- konjugering af modermolekylet og den dealkylerede metabolit.
Buprenorphine is metabolised by 14-N-dealkylation and glucuroconjugation of the parent molecule and the dealkylated metabolite.
Kliniske data bekræfter, at CYP3A4 er årsagen til N- dealkyleringen af buprenorphin.
10 dealkylation of buprenorphine.
N- dealkylbuprenorphin er en µ (my) - opioid agonist med ringe egenaktivitet.
N-dealkylbuprenorphine is a μ (mu)-opioid agonist with weak intrinsic activity.
Elimination af buprenorphin er bi - eller tri- eksponentiel med en gennemsnitlig plasmahalveringstid på 32 timer.
Elimination of buprenorphine is bi- or tri-exponential, and has a mean half-life from plasma of 32 hours.
Buprenorphin elimineres i fæces ved udskillelse af de glukoronidkonjugerede metabolitter i galden (70%), resten elimineres i urinen.
Buprenorphine is eliminated in the faeces by biliary excretion of the glucuroconjugated metabolites (70%), the rest being eliminated in the urine.
Efter intravenøs administration distribueres naloxon hurtigt (distributions halveringstid ~4 minutter).
Following intravenous administration, naloxone is rapidly distributed (distribution half-life ~ 4 minutes).
Efter peroral administration kan naloxon knapt detekteres i plasma; efter sublingual administration af Suboxone er naloxonplasmakoncentrationerne lave og falder hurtigt.
Following oral administration, naloxone is barely detectable in plasma; following sublingual administration of Suboxone, plasma naloxone concentrations are low and decline rapidly.
Præparatet metaboliseres i leveren, primært ved glukuronidkonjugering, og udskilles i urinen.
The medicinal product is metabolized in the liver, primarily by glucuronide conjugation, and excreted in the urine.
Naloxon har en gennemsnitlig plasmahalveringstid på 1, 2 timer.
Naloxone has a mean half-life from plasma of 1.2 hours.
Elimination via nyrerne spiller en relativt lille rolle (~30%) i den fuldstændige clearance for Suboxone.
Renal elimination plays a relatively small role (~30%) in the overall clearance of Suboxone.
Forsigtighed anbefales dog, når personer med svært nedsat nyrefunktion skal doseres.
No dose modification based on renal function is required but caution is recommended when dosing subjects with severe renal impairment.
Elimination via leveren spiller en relativt stor rolle (~70%) i den fuldstændige clearance for Suboxone, og virkningsvarigheden for buprenorphin kan være forlænget hos personer med nedsat leverclearance.
Hepatic elimination plays a relatively large role (~70%) in the overall clearance of Suboxone and the action of buprenorphine may be prolonged in subjects with impaired hepatic clearance.
Det kan være nødvendigt med lavere initiale Suboxone- doser og forsigtig dosisjustering hos patienter med let til moderat nedsat leverfunktion.
Lower initial Suboxone doses and cautious titration of dosage may be required in patients with mild to moderate hepatic dysfunction.
4. 3).
Suboxone is contraindicated in patients with severe hepatic dysfunction (see section 4.3).
I dyr har kombinationen af buprenorphin og naloxon været undersøgt i akutte og gentagne toksiske doser (op til 90 dage i rotter).
The combination of buprenorphine and naloxone has been investigated in acute and repeated dose (up to 90 days in rats) toxicity studies in animals.
Der er ikke observeret synergistisk øgning af toksisiteten.
No synergistic enhancement of toxicity has been observed.
Bivirkningerne kunne føres tilbage til den kendte farmakologiske aktivitet af opioid- agonistiske og/ eller antagonistiske stoffer.
Undesirable effects were based on the known pharmacological activity of opioid agonistic and/ or antagonistic substances.
Kombinationen var hverken klastigent i in vitro cytogenetisk assay med humane lymfocytter eller i en intravenøs mikronucleus test på rotter.
The combination (4:1) of buprenorphine hydrochloride and naloxone hydrochloride was not mutagenic in a bacterial mutation assay (Ames test), and was not clastogenic in an in vitro cytogenetic assay in human lymphocytes or in an intravenous micronucleus test in the rat.
Reproduktionsforsøg med oral indtagelse af buprenorphin: naloxon (forhold 1: 1) indikerede at embryoletalitet forekom hos rotter ved tilstedeværelse af maternal toksicitet ved alle doser.
Reproduction studies by oral administration of buprenorphine: naloxone (ratio 1:1) indicated that embryolethality occurred in rats in the presence of maternal toxicity at all doses.
Den laveste, undersøgte dosis repræsenterede udsættelse for buprenorphin 1x og 5x for naloxon ved den maksimale humane terapeutiske dosis udregnet på basis af mg/ m2.
The lowest dose studied represented exposure multiples of 1x for buprenorphine and 5x for naloxone at the maximum human therapeutic dose calculated on a mg/ m² basis.
Ved maternelt toksiske doser blev der ikke observeret udviklingstoksicitet hos kaniner.
No developmental toxicity was observed in rabbits at maternally toxic doses.
Der har derudover hverken været observeret teratogenicitet hos rotter eller hos kaniner.
Further, no teratogenicity has been observed in either rats or rabbits.
Oral indtagelse af høje doser buprenorphin hos hunner under drægtighed og diegivning resulterede i svær fødsel (muligvis på grund af buprenorphins sedative effekt), høj neonatal dødelighed og en mindre forsinkelse i udviklingen af nogle neurologiske funktioner (righting refeks og startle refleks) hos neonatale rotter.
A peri-postnatal study has not been conducted with Suboxone; however, maternal oral administration of buprenorphine at high doses during gestation and lactation resulted in difficult parturition (possible as a result of the sedative effect of buprenorphine), high neonatal mortality and a slight delay in the development of some neurological functions (surface righting reflex and startle response) in neonatal rats.
11 Suboxone som kosttilskud til rotter i doser på 500 ppm eller højere gav reduceret fertilitet i form af nedsat befrugtningsfrekvens hos hunrotter.
11 Dietary administration of Suboxone in the rat at dose levels of 500 ppm or greater produced a reduction in fertility demonstrated by reduced female conception rates.
2, 4x for buprenorphin ved en human dosis på 24 mg Suboxone baseret på AUC, plasmaniveauer for naloxon var under grænsen for detektion i rotter) havde ingen utilsigtet virkning på fertiliteten hos hunner.
A dietary dose of 100 ppm (estimated exposure approximately 2.4x for buprenorphine at a human dose of 24 mg Suboxone based on AUC, plasma levels of naloxone were below the limit of detection in rats) had no adverse effect on fertility in females.
En carcinogenicitetsundersøgelse med Suboxone blev udført med rotter i doser på 7, 30 og 120 mg/ kg/ dag, med estimerede ekponeringsmultipla på 3 til 75 gange, baseret på human daglig sublingual dosis på 16 mg beregnet ud fra mg/ m2.
A carcinogenicity study with Suboxone was conducted in rats at doses of 7, 30 and 120 mg/ kg/ day, with estimated exposure multiples of 3 to 75 times, based on a human daily sublingual dose of 16 mg calculated on a mg/ m² basis.
Der blev observeret statistisk signifikante stigninger i incidensen af benign testikel interstitiel (Leydigs) celle adenom i alle doseringsgrupper.
Statistically significant increases in the incidence of benign testicular interstitial (Leydig's) cell adenomas were observed in all dosage groups.
Laktosemonohydrat, Mannitol, Majsstivelse, Povidon K 30, Citronsyre, vandfri, Natriumcitrat, Magnesiumstearat, Acesulfamkalium, Naturlig citron og lime aroma.
Lactose monohydrate, Mannitol, Maize starch, Povidone K 30, Citric acid anhydrous, Sodium citrate, Magnesium stearate, Acesulfame potassium, Natural lemon and lime flavour.
7 resoribletter, sublinguale i blisterpakning Nylon/ Aluminium/ PVC.
7 tablets in blister packs Nylon/ Aluminum/ PVC.
28 resoribletter, sublinguale i blisterpakning Nylon/ Aluminium/ PVC.
28 tablets in blister packs Nylon/ Aluminum/ PVC.
Tiloversbleven medicin må ikke bortskaffes via spildevand eller via husholdningsaffald.
Medicines no longer required should not be disposed of via wastewater or the municipal sewage system.
Patienter bør instrueres i at returnere det til apoteket eller i at spørge apoteket, hvordan medicinen bortskaffes i overensstemmelse med lokale krav.
Patients should be instructed to return them to a pharmacy or to ask their pharmacist how to dispose of them in accordance with the national regulations.
26. september 2006
DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION 26 September 2006
Yderligere information om dette lægemiddel er tilgængelig på Det europæiske Lægemiddelagenturs (EMEAs) hjemmeside http: // www. emea. europa. eu
Detailed information on this product is available on the web-site of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Suboxone 8 mg/ 2 mg resoribletter, sublinguale
Suboxone 8 mg/ 2 mg sublingual tablets
Hver resoriblet indeholder 8 mg buprenorphin (som buprenorphinhydrochlorid) og 2 mg naloxon (som naloxonhydrochloriddihydrat).
Each tablet contains 8 mg buprenorphine (as buprenorphine hydrochloride) and 2 mg naloxone (as naloxone hydrochloride dihydrate).
Laktose 168 mg
Excipients: lactose 168 mg
Hvid, hexagonal, bikonveks resoriblet trykt med et logo i form af et sværd på den ene side og ” N8 ” på den modsatte side.
White hexagonal biconvex tablets, embossed with a sword logo on one side and “ N8” on the reverse side.
De Suboxone- tabletter, der indeholder 8 mg buprenorphin og 2 mg naloxon, omtales som ” 8 mg- tabletterne ”.
Suboxone containing 8 mg buprenorphine and 2 mg naloxone is referred to as the "8 mg" tablets.
14 Indledende behandling:
14 Induction:
Ved behandlingsstart anbefales det at udlevere buprenorphin dagligt.
During the initiation of treatment, daily dispensing of buprenorphine is recommended.
Efter stabilisering kan patienter, der anses for at være pålidelige, forsynes med Suboxone til flere dages behandling.
After stabilisation, a reliable patient may be given a supply of Suboxone sufficient for several days of treatment.
Ved tilfredsstillende stabilisering, kan frekvensen af Suboxone- dosering nedsættes til hver anden dag med den dobbelte individuelt justerede daglige dosis.
After a satisfactory stabilisation has been achieved the frequency of Suboxone dosing may be decreased to dosing every other day at twice the individually titrated daily dose.
Patienter med nedsat leverfunktion:
15 Patients with impaired hepatic function:
15 Patienter med nedsat nyrefunktion:
Patients with impaired renal function:
Suboxone kan forårsage døsighed, særligt ved samtidig indtag af alkohol eller CNS- hæmmere (såsom beroligende midler, sedativa eller hypnotika) (se pkt.
16 Suboxone may cause drowsiness, particularly when taken together with alcohol or central nervous system depressants (such as tranquilisers, sedatives or hypnotics) (see section 4.5).
16 Der er rapporteret om dødsfald i forbindelse med samtidig indtagelse af buprenorphin og andre hæmmende midler som alkohol eller andre opioider.
Deaths have been reported in association with concomitant administration of buprenorphine and other depressants such as alcohol or other opioids.
• benzodiazepiner:
17 • benzodiazepines:
18 4. 8 Bivirkninger
4.8 Undesirable effects
De mest almindelige behandlingsrelaterede bivirkninger rapporteret i kliniske undersøgelser med Suboxone var relateret til abstinenssymptomer (f. eks. mavesmerter, diarré, muskelsmerter, angst, svedeture).
18 The most common-treatment related undesirable effects reported during clinical trials with Suboxone were those related to withdrawal symptoms (e. g. abdominal pain, diarrhoea, muscle aches, anxiety, sweating).
Disse bivirkninger er opstillet i tabel 1 i systemorganklasser i henhold tilMedDRA- databasen og hyppighed (meget almindelig (> 1/ 10), almindelig (> 1/ 100, < 1/ 10), ikke almindelig (> 1/ 1. 000, ≤1/ 100).
These reactions are listed in Table 1 by system organ class and frequency (very common (> 1/ 10), common (> 1/ 100 ,< 1/10), uncommon (> 1/ 1,000 to ≤ 1/ 100).
19 Luftveje, thorax og mediastinum
19 Vascular disorders
4. 4), • hallucinationer, • tilfælde af bronkospasmer, angioneurotisk ødem og anafylaktisk shock.
20 • cases of bronchospasm, angioneurotic oedema and anaphylactic shock.
20 Hos patienter med udpræget stofafhængighed kan initial administration af buprenorphin forårsage abstinenser tilsvarende de, som er forbundet med naloxon.
In patients presenting with marked drug dependence, initial administration of buprenorphine can produce a withdrawal effect similar to that associated with naloxone.
Spontan abort har været rapporteret med både buprenorphin og buprenorphin- naloxon.
Spontaneous abortion has been reported with both buprenorphine and buprenorphine-naloxone.
Ved behandling af en overdosis skal Suboxones lange virkningvarighed skal tages i betragtning under fastlæggelsen af behandlingens og den medicinske overvågnings varighed.
The long duration of action of Suboxone should be taken into consideration when determining the length of treatment and medical surveillance needed to reverse the effects of an overdose.
I denne
Efficacy and safety data for Suboxone are primarily derived from a one-year clinical trial, comprising a 4-week randomised double blind comparison of Suboxone, buprenorphine and placebo tablets followed by a 48 week safety study of Suboxone.
21 undersøgelse blev 326 heroinmisbrugere randomiseret til enten Suboxone 16 mg per dag, 16 mg buprenorphin per dag eller placebo- tabletter.
In this trial, 326 heroin-addicted subjects were randomly assigned to either Suboxone 16 mg per day, 16 mg buprenorphine per day or placebo tablets.
Til de personer, der var randomiseret til aktiv behandling begyndte dosering med en 8 mg buprenorphin- tablet på dag 1, fulgt af 16 mg (to 8 mg tabletter) buprenorphin på dag 2.
For subjects randomized to either active treatment, dosing began with one 8 mg tablet of buprenorphine on Day 1, followed by 16 mg (two 8 mg tablets) of buprenorphine on Day 2.
22 Metabolisme og elimination:
22 dealkylation of buprenorphine.
23 Suboxone som kosttilskud til rotter i doser på 500 ppm eller højere gav reduceret fertilitet i form af nedsat befrugtningsfrekvens hos hunrotter.
23 Dietary administration of Suboxone in the rat at dose levels of 500 ppm or greater produced a reduction in fertility demonstrated by reduced female conception rates.
BETINGELSENER FOR MARKEDSFØRINGSTILLADELSEN
CONDITIONS OF THE MARKETING AUTHORISATION
Navn og adresse på fremstillen ansvarlig for batchfrigivelse
Name and address of the manufacturers responsible for batch release
Reckitt Benckiser Healthcare (UK) Ltd Dansom Lane Hull, East Yorkshire HU8 7DS England
Reckitt Benckiser Healthcare (UK) Ltd Dansom Lane Hull, East Yorkshire HU8 7DS United Kingdom
Lægemidlet må kun udleveres efter begrænset og særlig recept (jf. bilag I:
Medicinal product subject to special and restricted medical prescription (See Annex I:
Substitutionsbehandling for stofafhængighed med opioider er påtænkt til anvendelse hos voksne og unge over 15 år, der har indvilliget i at blive behandlet for misbrug, indenfor en ramme af medicinsk, social og psykologisk behandling, af læger med erfaring i behandlingen af opioidafhængighed / - misbrug.
Substitution treatment for opioid drug dependence is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction, within a framework of medical, social and psychological treatment, by physicians experienced in the treatment of opiate dependence/ addiction.
Indehaveren af markedsføringstilladelsen skal sikre at bivirkningssystemet er i orden og fungerer, før produktet kommer på markedet og så længe at det markedsførte produkt stadig anvendes.
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market and for as long as the marketed product remains in use.
Indehaveren af markedsføringstilladelsen forpligter sig til at udføre undersøgelserne og yderligere bivirkningsaktiviteter beskrevet i Bivirkningsplanen.
The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan.
En opdateret Risk Management Plan bør være vedlagt i henhold til CHMP Guideline om Risk Management Systemer for lægemidler til human anvendelse.
An updated Risk Management Plan should be provided as per the CHMP Guideline on Risk Management Systems for medicinal products for human use.
PAKNINGER Á 7 OG 28 RESORIBLETTER 2 MG
PACK OF 7 and 28 TABLETS 2 MG STRENGTH
Suboxone 2 mg/ 0, 5 mg resoribletter, sublinguale buprenorphin / naloxon
Suboxone 2 mg/ 0.5 mg sublingual tablets buprenorphine / naloxone
Hver resoriblet, sublingual indeholder 2 mg buprenorphin som buprenorphinhydrochlorid og 0, 5 mg naloxon som naloxonhydrochloriddihydrat
Each sublingual tablet contains 2 mg buprenorphine as buprenorphine hydrochloride and 0.5 mg naloxone as naloxone hydrochloride dihydrate.
Indeholder laktosemonohydrat Se indlægsseddel for yderligere information.
See leaflet for further information.
7 resoribletter, sublinguale 28 resoribletter, sublinguale
7 sublingual tablets 28 sublingual tablets
Må ikke sluges.
Sublingual use Do not swallow.
EU/ 1/ 06/ 359/ 001 7 resoribletter, sublinguale EU/ 1/ 06/ 359/ 002 28 resoribletter, sublinguale
EU/ 1/ 06/ 359/ 001 EU/ 1/ 06/ 359/ 002
PAKNINGER Á 7 OG 28 RESORIBLETTER 8 MG
PACK OF 7 and 28 TABLETS 8 MG STRENGTH
Suboxone 8 mg/ 2 mg resoribletter, sublinguale buprenorphin / naloxon
Suboxone 8 mg/ 2 mg sublingual tablets buprenorphine / naloxone
Hver resoriblet, sublingual indeholder 8 mg buprenorphin som buprenorphinhydrochlorid og 2 mg naloxon som naloxonhydrochloriddihydrat
Each sublingual tablet contains 8 mg buprenorphine as buprenorphine hydrochloride and 2 mg naloxone as naloxone hydrochloride dihydrate.
EU/ 1/ 06/ 359/ 003 7 resoribletter, sublinguale EU/ 1/ 06/ 359/ 004 28 resoribletter, sublinguale
EU/ 1/ 06/ 359/ 003 EU/ 1/ 06/ 359/ 004
33 MINDSTEKRAV TIL OPLYSNINGER PÅ BLISTERKORT ELLER BLISTERSTRIPS
33 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
Suboxone 2 mg/ 0, 5 mg resoribletter, sublinguale buprenorphin/ naloxon
Suboxone 2 mg/ 0.5 mg sublingual tablets buprenorphine / naloxone
- Lægen har ordineret Suboxone til dig personligt.
- This medicine has been prescribed for you.
Lad derfor være med at give Suboxone til
It may harm them, even
Suboxones virkning og hvad du skal bruge det til 2.
What Suboxone is and what it is used for 2.
Det skal du vide, før du begynder at tage Suboxone 3.
Before you take Suboxone 3.
Sådan skal du tage Suboxone 4.
How to take Suboxone 4.
Sådan opbevarer du Suboxone 6.
Possible side effects 5 How to store Suboxone 6.
SUBOXONES VIRKNING OG HVAD DU SKAL BRUGE DET TIL
WHAT SUBOXONE IS AND WHAT IT IS USED FOR
Lægemiddel mod opioidafhængighed.
Medicinal product used in opioid dependence.
Suboxone er en del af et medicinsk, socialt og psykologisk behandlingsprogram for patienter, som er afhængige af opioider (narkotika).
Suboxone is part of a medical, social and psychological treatment programme for patients addicted to opiate (narcotic) drugs.
Behandling er foreskreven og overvåget af læger, der er specialister i behandlingen af stofafhængighed.
Treatment is prescribed and monitored by physicians who are specialists in the treatment of drug dependence.
Behandling med Suboxone- resoribletter, sublinguale, er beregnet til voksne og unge over 15 år.
Treatment with Suboxone sublingual tablets is intended for use in adults and adolescents over 15 years of age.
DET SKAL DU VIDE, FØR DU BEGYNDER AT TAGE SUBOXONE
BEFORE YOU TAKE SUBOXONE
- hvis du er overfølsom (allergisk) over for buprenorphin, naloxon eller et af de øvrige
- if you are allergic (hypersensitive) to buprenorphine, naloxone or any of the other ingredients of
indholdsstoffer.
Suboxone,
- hvis du har alvorlige vejrtrækningsproblemer,
- if you have serious breathing problems,
- hvis du har alvorlige leverproblemer,
- if you have serious problems with your liver,
- hvis du er beruset af alkohol eller har delirium tremens.
- if you are intoxicated due to alcohol or have delirium tremens.
Vær ekstra forsigtig med at tage Suboxone Forkert brug og misbrug Enkelte personer er døde af respirationssvigt (manglende vejrtrækning), fordi de har misbrugt buprenorphin eller har taget det i kombination med andre hæmmere af centralnervesystemet, såsom alkohol, benzodiazepiner (beroligende midler) eller andre opioider (narkotika).
Take special care with Suboxone Misuse and abuse Some people have died from respiratory failure (inability to breathe) because they misused buprenorphine or took it in combination with other Central Nervous System depressants, such as alcohol, benzodiazepines (tranquilisers), or other opioids.
Der er set tilfælde af akut leverskade (leverproblemer) i forbindelse med misbrug, især ved intravenøs brug og i høje doser.
Cases of acute hepatic injury (liver problems) have been reported in a context of misuse, especially by intravenous route and at a high dose.
Disse skader kan skyldes særlige tilstande som infektioner på grund af virus (kronisk hepatitis C), alkoholmisbrug, spisevægring eller brug af medicin (f. eks.: antiretrovirale nukleosid analoger, acetylsalicylsyre (aspirin), amiodaron, isoniazid, valproat).
These injuries could be due to special conditions as viral infections (chronic C hepatitis), alcohol abuse, anorexia, or medicines association (for example: antiretroviral nucleoside analogues, acetylsalicylic acid (aspirin), amiodarone, isoniazid, valproate).
Stærk træthed, kløe, eller hvis din hud eller øjne ser gule ud.
If you have symptoms of severe fatigue, itching, or if your skin or eyes look yellow, tell your doctor immediately, so that you can receive the proper treatment.
Det samme gælder, hvis du tager Suboxone mindre end 24 timer efter, du har taget metadon.
37 This product can cause withdrawal symptoms if you take it less than six hours after you use a narcotic (e. g. morphine, heroin) or less than 24 hours after you use methadone.
Denne medicin kan forårsage søvnighed, som kan forstærkes af alkohol eller angstdæmpende medicin.
This product can cause sleepiness which may be increased by alcohol or anti-anxiety medicines.
Tal med lægen i tilfælde af:
Advise your physician in case of:
- nylige kvæstelser i hovedet eller sygdom i hjernen,
- recent head injury or brain disease,
- blodtryksfald
- decrease of blood pressure,
- hos mænd: vandladningsbesvær (særligt forbundet med forstørret prostata).
- in men: urinary disorders (especially linked to enlarged prostate).
Dette lægemiddel kan gøre, at du ikke mærker de smerter, som nogle sygdomme fremkalder.
This medicinal product may mask pain reflecting some diseases.
Husk at fortælle til din egen læge, at du tager dette lægemiddel.
Do not forget to advise your physician if you take this medicine.
Denne medicin kan forårsage, at dit blodtryk falder pludseligt, og at du føler dig svimmel, hvis du rejser dig hurtigt op, efter at du har siddet eller ligget ned.
This product may cause your blood pressure to drop suddenly, causing you to feel dizzy if you get up too quickly from sitting or lying down.
Denne medicin kan forårsage afhængighed.
This product can cause dependence.
Sportsfolk bør være opmærksomme på, at denne medicin kan give positiv reaktion på anti doping- tests på grund af det aktive indholdsstof.
Athletes should be aware that this medicine, due to its active substance, may cause a positive reaction to “ anti-doping tests”.
- astma eller andre vejrtrækningsproblemer,
- asthma or other breathing problems,
- nyresygdom,
- kidney disease,
- leversygdom
- liver disease.
Brug af de lægemidler, der er nævnt nedenfor, skal følges nøje: • beroligende midler • angstdæmpende midler • antidepressive midler • benzodiazepiner • visse lægemidler anvendt til behandling af højt blodtryk.
Using other medicines Using other medicines may increase the undesirable effects of buprenorphine and use of these medicines must be carefully monitored: • tranquilizers • anti-anxiety medicines • anti-depressants • benzodiazepines • some medicines used to treat high blood pressure.